256 related articles for article (PubMed ID: 23079784)
1. Role of autologous bone marrow transplant in multiple myeloma.
Blanes M; de la Rubia J
Curr Opin Oncol; 2012 Nov; 24(6):733-41. PubMed ID: 23079784
[TBL] [Abstract][Full Text] [Related]
2. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
3. Second autologous transplant as salvage therapy in multiple myeloma.
Atanackovic D; Schilling G
Br J Haematol; 2013 Dec; 163(5):565-72. PubMed ID: 24111632
[TBL] [Abstract][Full Text] [Related]
4. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs.
Morabito F; Gentile M; Mazzone C; Bringhen S; Vigna E; Lucia E; Recchia AG; Raimondo FD; Musto P; Palumbo A
Eur J Haematol; 2010 Sep; 85(3):181-91. PubMed ID: 20491882
[TBL] [Abstract][Full Text] [Related]
6. Intensive treatment strategies in multiple myeloma.
Kovacsovics TJ; Delaly A
Semin Hematol; 1997 Jan; 34(1 Suppl 1):49-60. PubMed ID: 9122746
[TBL] [Abstract][Full Text] [Related]
7. Role of consolidation therapy in transplant eligible multiple myeloma patients.
Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
[TBL] [Abstract][Full Text] [Related]
8. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
9. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
Moreau P; Giralt SA
Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
[TBL] [Abstract][Full Text] [Related]
10. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
11. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
12. Novel approaches in myeloma therapy.
Munshi NC; Barlogie B; Desikan KR; Wilson C
Semin Oncol; 1999 Oct; 26(5 Suppl 13):28-34. PubMed ID: 10528892
[TBL] [Abstract][Full Text] [Related]
13. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
14. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
15. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic.
Gibson J; Ho PJ; Joshua D
Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295
[TBL] [Abstract][Full Text] [Related]
16. [Intensive treatment of multiple myeloma].
Harousseau JL
Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
Klepin HD; Hurd DD
Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
[TBL] [Abstract][Full Text] [Related]
18. New questions about transplantation in multiple myeloma.
Hari P; Pasquini MC; Vesole DH
Oncology (Williston Park); 2006 Sep; 20(10):1230-42; discussion 1242, 1244, 1249-50. PubMed ID: 17024872
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of multiple myeloma--melphalan monotherapy after bone marrow transplantation].
Hájek R; Adam Z; Krejcí M; Vásová I; Král Z; Vorlícek J
Vnitr Lek; 1996 Apr; 42(4):278-84. PubMed ID: 8693716
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
